LEADER 03883nam  22009253u 450 
001 9910972032203321
005 20240416172505.0
010   $a9782742012343
010   $a2742012346
035   $a(CKB)3710000000025020
035   $a(EBL)3317898
035   $a(SSID)ssj0001048635
035   $a(PQKBManifestationID)12381905
035   $a(PQKBTitleCode)TC0001048635
035   $a(PQKBWorkID)11017933
035   $a(PQKB)11028185
035   $a(PPN)185797083
035   $a(FR-PaCSA)88821148
035   $a(MiAaPQ)EBC3317898
035   $a(FRCYB88821148)88821148
035   $a(BIP)50484048
035   $a(EXLCZ)993710000000025020
100   $a20151005d2014||||  u||         |
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aOrphan Drugs in Epilepsy
205   $a1st ed.
210   $aMontrouge $cJOHN LIBBEY EUROTEXT$d2014
215   $a1 online resource (90 p.)
225 1 $aTopics in Epilepsy ;$vv.4
300   $aDescription based upon print version of record.
311 08$a9782742008100 
311 08$a2742008101 
327   $a""Orphan Drugs in Epilepsy""; ""Contents""; ""Foreword""; ""Bromides""; ""Adrenocorticotropic hormone and corticosteroids""; ""Stiripentol""; ""Felbamate""; ""Rufinamide""
330   $aOver half of epilepsies start before the age of 20 years and nearly 25% of them are refractory. A tiny proportion of them are even labelled a rare illness (ie: one affecting less than 200,000 people in the United States or less than 5 out of 10,000 people in the European Union). For these patients, two problems in their management arise: In children, seizures affect an immature brain and can impact its development. It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
410  0$aTopics in Epilepsy
606   $aEpilepsy -- Treatment
606   $aBrain Diseases
606   $aCentral Nervous System Agents
606   $aDrug Industry
606   $aIndustry
606   $aTherapeutic Uses
606   $aCentral Nervous System Diseases
606   $aNervous System Diseases
606   $aTechnology, Industry, and Agriculture
606   $aPharmacologic Actions
606   $aChemical Actions and Uses
606   $aDisease
606   $aAnticonvulsants
606   $aEpilepsy
606   $aOrphan Drug Production
615  4$aEpilepsy -- Treatment.
615  2$aBrain Diseases.
615  2$aCentral Nervous System Agents.
615  2$aDrug Industry.
615  2$aIndustry.
615  2$aTherapeutic Uses.
615  2$aCentral Nervous System Diseases.
615  2$aNervous System Diseases.
615  2$aTechnology, Industry, and Agriculture.
615  2$aPharmacologic Actions.
615  2$aChemical Actions and Uses.
615  2$aDisease.
615  2$aAnticonvulsants.
615  2$aEpilepsy.
615  2$aOrphan Drug Production.
676   $a616.853
700   $aNikanorova$b Marina$01796203
701   $aJohannessen$b S. I$01864973
701   $aGenton$b Pierre$01679223
801  0$bAU-PeEL
801  1$bAU-PeEL
801  2$bAU-PeEL
906   $aBOOK
912   $a9910972032203321
996   $aOrphan Drugs in Epilepsy$94471957
997   $aUNINA